Fairvalue-Calculator Fairvalue-Calculator
EN DE

HLS Therapeutics Inc (HLTRF) Fair Value & Analysis

Healthcare · US · Market cap $98.8M

Price$3.16
Fair Value$6.85
Upside+116.8%
Quality95/100
Evidence: Medium Range $4.83 – $8.87

Fair value as of: Jun 25, 2026

Analysis

HLS Therapeutics Inc (HLTRF) currently trades at $3.16, while our model-based Fair Value estimate is $6.85 — implying the stock looks roughly 116.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, arip…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is HLS Therapeutics Inc (HLTRF) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $6.85 versus a price of $3.16 — about +117% (undervalued). Model-based estimate, not financial advice.
What is the fair value of HLTRF?
Our 21-model fair value for HLS Therapeutics Inc is $6.85 (as of Jun 25, 2026), built from audited fundamentals. The current price is $3.16.
What is the quality score of HLTRF?
HLS Therapeutics Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.